Literature DB >> 19018828

Autologous fat transplantation for depressed linear scleroderma-induced facial atrophic scars.

Mi Ryung Roh1, Jin Young Jung, Kee Yang Chung.   

Abstract

BACKGROUND: Facial linear scleroderma results in depressed atrophic scars. Autologous fat transplantation has been widely used, and fat appears to be an ideal material for filling depressed atrophic scars and contour deformities, but long-term results for autologous fat transplantation are controversial.
OBJECTIVE: To review the short- and long-term results of 20 patients who underwent multiple autologous fat transplantations for depressed atrophic scar correction.
METHODS: Twenty patients with clinically inactive facial linear scleroderma were included. They received at least two transplantations and had a 12-month follow-up evaluation.
RESULTS: On the forehead, 51% to 75% improvement (average grading scale: 2.4) was achieved when observed at least 12 months after the last treatment. For the chin, correction was poor (average grading scale: 0.7) with less than 25% improvement. The infraorbital area showed fair correction, but the nose showed poor correction. Two of three patients with scalp reduction surgery showed excellent results, showing only slight scar widening.
CONCLUSIONS: Autologous fat transplantation is an effective method for long-term correction of depressed atrophic scars left by linear scleroderma on the forehead but is less effective for corrections on the nose, infraorbital area, and chin.

Entities:  

Mesh:

Year:  2008        PMID: 19018828     DOI: 10.1111/j.1524-4725.2008.34343.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  8 in total

Review 1.  Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.

Authors:  Ming Zhao; Jiali Wu; Haijing Wu; Amr H Sawalha; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-15       Impact factor: 8.667

2.  A pilot study on ex vivo expanded autologous adipose-derived stem cells of improving fat retention in localized scleroderma patients.

Authors:  Chenyu Wang; Xiao Long; Loubin Si; Bo Chen; Yiwei Zhang; Tianyu Sun; Xiuqin Zhang; Robert Chunhua Zhao; Xiaojun Wang
Journal:  Stem Cells Transl Med       Date:  2021-04-19       Impact factor: 6.940

Review 3.  Evaluating evidence for atrophic scarring treatment modalities.

Authors:  Lopa Patel; Duncan McGrouther; Kaushik Chakrabarty
Journal:  JRSM Open       Date:  2014-08-11

Review 4.  Facial Fat Grafting (FFG): Worth the Risk? A Systematic Review of Complications and Critical Appraisal.

Authors:  Luigi Schiraldi; Gianluca Sapino; Joachim Meuli; Michele Maruccia; Mario Cherubino; Wassim Raffoul; Pietro G di Summa
Journal:  J Clin Med       Date:  2022-08-11       Impact factor: 4.964

5.  Treatment of Linear Morphea (en Coup de Sabre) with Micronized Acellular Dermal Matrix Filler: A Case Report.

Authors:  Jemin Kim; Jihee Kim; Young In Lee; Ju Hee Lee
Journal:  Ann Dermatol       Date:  2021-07-01       Impact factor: 1.444

6.  Implantation of autologous fat globules in localized scleroderma and idiopathic lipoatrophy--report of five patients.

Authors:  Tiago Pina Zanelato; Giovana Marquesini; Paula Tavares Colpas; Renata Ferreira Magalhães; Aparecida Machado de Moraes
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

7.  Parry-Romberg syndrome with hemimasticatory spasm in pregnancy; A dystonia mimic.

Authors:  Akhila Kumar Panda; Godhavarma Gopinath; Shaily Singh
Journal:  J Neurosci Rural Pract       Date:  2014-04

8.  Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients.

Authors:  Francesco Virzì; Paola Bianca; Alessandro Giammona; Tiziana Apuzzo; Simone Di Franco; Laura Rosa Mangiapane; Maria Luisa Colorito; Dario Catalano; Emanuela Scavo; Annalisa Nicotra; Antonina Benfante; Giuseppe Pistone; Valentina Caputo; Francesco Dieli; Roberto Pirrello; Giorgio Stassi
Journal:  Stem Cell Res Ther       Date:  2017-10-23       Impact factor: 6.832

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.